Clinical Comprehensive Evaluation on Hemocoagulase Drugs Based on A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition)
10.3870/j.issn.1004-0781.2025.02.012
- VernacularTitle:基于《中国医疗机构药品评价与遴选快速指南(第二版)》的血凝酶类药物临床综合评价
- Author:
Yayun WANG
1
;
Anhua WEI
;
Lu WANG
;
Xuepeng GONG
;
Dong LIU
;
Lu ZENG
Author Information
1. 华中科技大学同济医学院附属同济医院药学部,武汉 430030;湖北省监利市人民医院药剂科,监利 433300
- Publication Type:Journal Article
- Keywords:
Hemocoagulase drugs;
Hemostatic drugs;
Drug evaluation;
Drug selection
- From:
Herald of Medicine
2025;44(2):245-250
- CountryChina
- Language:Chinese
-
Abstract:
Objective The multi-dimensional evaluation of hemocoagulase drugs was carried out to provide reference data for clinical drug use and drug selection in medical institutions.Methods According to the evaluation system established by the A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition),part of the scoring rules was adjusted,and relevant literatures from CNKI,Wanfang,VIP,PubMed,Embase,Cochrane Library and other databases were referred to.Four hemocoagulase drugs listed in China were quantitatively scored from five dimensions:pharmaceutical properties,effectiveness,safety,economy and other attributes(medical insurance,essential drugs,manufacturers,etc.).The recommendation levels were divided according to the scoring results.Results The quantified scoring results,in descending order,were ashaemocoagulaseagkistrodon(HCA)(68.50 points),hemocoagulaseagkistrodonhalys(HAH)(59.89 points),hemocoagulase injection(HI)(52.84 points)and hemocoagulasebothropsatrox(HBA)(49.31 points).Conclusions The overall score of hemocoagulase drugs is low,and other hemostatic drugs can be preferred when alternative drugs are available.Among them,the HCA is weakly recommended in medical institutions.This study can provide reference for the selection of hemocoagulase drugs in medical institutions,and also provide basis for clinical rational drug use.
